Holen Sie sich die Stockscreener-App
29.42
1.85%
-0.5176
Schlusskurs vom Vortag:
$29.94
Offen:
$30.1
24-Stunden-Volumen:
372.37K
Relative Volume:
0.30
Marktkapitalisierung:
$3.16B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-150.70M
KGV:
-18.98
EPS:
-1.55
Netto-Cashflow:
$-125.67M
1W Leistung:
+5.63%
1M Leistung:
-2.08%
6M Leistung:
+106.36%
1J Leistung:
+16.24%
1-Tages-Spanne:
$29.01
$31.36
1-Wochen-Bereich:
$27.03
$31.38
52-Wochen-Spanne:
$10.60
$31.82
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
29.45 | 3.21B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.70 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.79 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.66 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Eingeleitet | Goldman | Neutral |
| 2025-07-30 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-30 | Eingeleitet | Guggenheim | Buy |
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
A Look At Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term Sevasemten Becker Data - simplywall.st
Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors - TipRanks
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
EWTX: 7500 advances toward Phase III in HCM, with Becker data showing disease stabilization - TradingView
American Century Companies Inc. Buys 312,307 Shares of Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise reports functional stability in Becker dystrophy trial By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock after trial data - Investing.com Canada
Truist reiterates Edgewise Therapeutics stock rating on trial data - Investing.com India
Edgewise reports functional stability in Becker dystrophy trial - Investing.com Nigeria
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up - PR Newswire
Will Edgewise Therapeutics Inc stock recover after earningsPortfolio Return Report & Long-Term Capital Growth Ideas - baoquankhu1.vn
EPS Watch: Will Edgewise Therapeutics Inc stock hit new highs in YEAR2026 Highlights & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Edgewise’s New EDG-7500 Study Signals Broader Cardiovascular Ambitions - The Globe and Mail
Trading Systems Reacting to (EWTX) Volatility - Stock Traders Daily
Vanguard Group Inc. Has $77.92 Million Stake in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Aug PreEarnings: Is Edgewise Therapeutics Inc being accumulated by smart money2025 Valuation Update & Daily Stock Momentum Reports - baoquankhu1.vn
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Edgewise Therapeutics to Present at Leerink Global Healthcare Conference on March 11, 2026 - geneonline.com
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 - Yahoo Finance
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Unpacking A 35.24% Upside Potential - DirectorsTalk Interviews
Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - 富途牛牛
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference - PR Newswire
EWTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Edgewise Therapeutics (EWTX) Is Down 6.8% After Wider 2025 Losses And New BMD Data Plans – Has The Bull Case Changed? - Sahm
Edgewise Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Three new Edgewise hires get options to buy 51,000 shares - Stock Titan
Citigroup Inc. Sells 186,446 Shares of Edgewise Therapeutics, Inc. $EWTX - MarketBeat
FY2026 Earnings Forecast for EWTX Issued By HC Wainwright - MarketBeat
Investor Mood: Will Edgewise Therapeutics Inc stock hit new highs in YEARJuly 2025 Trade Ideas & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Aug Reactions: Is Edgewise Therapeutics Inc stock forming a cup and handleTrade Exit Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Artisan Partners Limited Partnership Reduces Stake in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Stock Rating Upgraded by HC Wainwright - MarketBeat
Assessing Edgewise Therapeutics (EWTX) Valuation As Earnings And Key Clinical Milestones Draw Closer - simplywall.st
Edgewise Therapeutics (NASDAQ:EWTX) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Evercore Maintains Outperform, PT $45 for Edgewise Therapeutics (EWTX) Feb 2026 - Meyka
Q1 Earnings Estimate for EWTX Issued By HC Wainwright - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Posts Earnings Results - MarketBeat
Evercore ISI raises Edgewise Therapeutics price target on HCM data By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Edgewise Therapeutics stock - Investing.com UK
Edgewise Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Stifel raises Edgewise Therapeutics stock price target on trial data timeline - Investing.com Canada
Edgewise Therapeutics Q4 Net Loss Widens From Previous Quarter - marketscreener.com
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q4 Net Loss $0.47 a Share, vs. FactSet Est of $0.40 Loss - marketscreener.com
Edgewise Therapeutics, Inc. SEC 10-K Report - TradingView
Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi‑Year Returns And Recent Share Price Momentum - Yahoo Finance
Edgewise Therapeutics Q4 net loss widens vs Q3 as costs rise - TradingView
Edgewise (Nasdaq: EWTX) ups R&D spending as Q4 2025 loss widens - Stock Titan
BRIEF-Edgewise Therapeutics Q4 Operating Income USD -55.979 Million - TradingView
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs - PR Newswire
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Edgewise Therapeutics Inc-Aktie (EWTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Edris Badreddin | Director |
Jan 21 '26 |
Sale |
29.44 |
115,471 |
3,399,466 |
19,820 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):